Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer. A phase I/II study of the ...

Head and neck cancer in octogenarians: A single center experience. Are signatures of radiosensitivity ready for routine clinical use? A pragmatic comparison of clinical, pathological, and gene ...

People who receive monoclonal antibodies before vaccines may benefit from increased coverage, due to antibody feedback inhibition, according to new research. Nearly three years into the pandemic, many ...

Nearly three years into the pandemic, many of us now carry antibodies against the virus - due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment. But not ...

Nearly three years into the pandemic, many of us now carry antibodies against the virus—due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment. But not ...